BioTelemetry Inc
Find Ratings ReportsBIOTELEMETRY INC's gross profit margin for the second quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased. BIOTELEMETRY INC has strong liquidity. Currently, the Quick Ratio is 1.72 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 65.85% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
| Income Statement | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Net Sales ($mil) | 58.13 | 52.68 |
| EBITDA ($mil) | 12.86 | 9.2 |
| EBIT ($mil) | 9.04 | 5.54 |
| Net Income ($mil) | 1.73 | 4.7 |
| Balance Sheet | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Cash & Equiv. ($mil) | 26.9 | 25.44 |
| Total Assets ($mil) | 203.95 | 156.19 |
| Total Debt ($mil) | 24.8 | 37.76 |
| Equity ($mil) | 146.78 | 88.5 |
| Profitability | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Gross Profit Margin | 66.74 | 67.56 |
| EBITDA Margin | 22.13 | 17.46 |
| Operating Margin | 15.55 | 10.51 |
| Sales Turnover | 1.08 | 1.23 |
| Return on Assets | 22.83 | 9.04 |
| Return on Equity | 31.72 | 15.95 |
| Debt | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Current Ratio | 2.03 | 2.07 |
| Debt/Capital | 0.14 | 0.3 |
| Interest Expense | 0.0 | 0.0 |
| Interest Coverage | 0.0 | 0.0 |
| Share Data | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Shares outstanding (mil) | 28.74 | 28.03 |
| Div / share | 0.0 | 0.0 |
| EPS | 0.05 | 0.15 |
| Book value / share | 5.11 | 3.16 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 402358.0 | 529544.0 |
BUY. The current P/E ratio indicates a premium compared to an average of 23.80 for the Health Care Providers & Services industry and a value on par with the S&P 500 average of 24.88. For additional comparison, its price-to-book ratio of 7.27 indicates a significant premium versus the S&P 500 average of 3.10 and a significant premium versus the industry average of 3.33. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, BIOTELEMETRY INC proves to trade at a premium to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BEAT 24.57 | Peers 23.80 | BEAT 33.05 | Peers 11.90 | |||||||||||||||||||||
|
Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation. BEAT is trading at a valuation on par with its peers. |
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. BEAT is trading at a significant premium to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| BEAT 26.13 | Peers 16.92 | BEAT NM | Peers 0.71 | |||||||||||||||||||||
|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. BEAT is trading at a significant premium to its peers. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. BEAT's negative PEG ratio makes this valuation measure meaningless. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| BEAT 7.27 | Peers 3.33 | BEAT 221.27 | Peers 20.55 | |||||||||||||||||||||
|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. BEAT is trading at a significant premium to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. BEAT is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| BEAT 4.82 | Peers 0.92 | BEAT 15.36 | Peers 8.42 | |||||||||||||||||||||
|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. BEAT is trading at a significant premium to its industry. |
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share. BEAT has a sales growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
